News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 85–96 of 243 stories

Aptamer Group Partners with Pharmahungary on Heart and Muscle Delivery Vehicles

Aptamer Group has agreed a research collaboration with Pharmahungary to build Optimer targeting vehicles for heart and skeletal muscle cells, carrying Pharmahungary's therapeutic microRNA. Costs are shared, with Pharmahungary funding the preclinical programme, and Aptamer will hold a 50% stake in the combined therapeutic. The aim is preclinical data to support joint licensing deals.

Biographica Introduces CROP-1 AI Model for Crop Gene Regulation

Biographica has introduced CROP-1, a genomic AI model combining DNA sequence and biological context to predict gene expression across crops and conditions. The company reports stronger computational prediction results than several comparison models and describes possible applications in targeted crop trait development. Its proposed regulatory edits remain predictions, not experimentally demonstrated improvements in plants. The accompanying research manuscript has not yet undergone peer review.

Microbiotica Presents Phase 1b MELODY-1 Data for MB097 with Keytruda in Refractory Melanoma

Microbiotica has presented Phase 1b MELODY-1 data at ESMO 2026 for MB097, its nine-strain live biotherapeutic, given with Keytruda to 41 melanoma patients who had not responded to anti-PD-1 therapy. Objective responses were seen in 14% of patients who received vancomycin preconditioning and 10% of those who did not, including one complete response, with no serious adverse events related to MB097.

Pharmanovia Presents Updated Phase 3 FLAMES Data for Senaparib in Ovarian Cancer

Pharmanovia has presented updated Phase 3 FLAMES data at ESMO 2026 showing median progression-free survival of 38.7 months with senaparib versus 13.6 months with placebo as first-line maintenance in advanced ovarian cancer (HR 0.47). Pharmanovia holds rights to senaparib across 66 countries including the EU and UK, and the drug received a positive CHMP opinion in September and awaits a European Commission decision.

U-Ploid's LYVANTA Nearly Doubles Share of Error-Free Human Eggs in Lab Study

U-Ploid Biotechnologies has reported that its investigational therapy LYVANTA (UP-085) raised the share of chromosomally error-free human eggs to 65.6% from 35.7% in a randomised laboratory study using eggs donated at six UK fertility clinics, presented at ASRM 2026. The results are preclinical, and safety studies and clinical trials are still needed.

Funding & Grants26 Oct 2026

adsilico Raises £10M Series A to Extend Virtual Patient Testing to Brain Devices

adsilico has raised a £10 million Series A led by PXN Ventures, with existing investors Northern Gritstone and Parkwalk taking part, to extend its virtual heart and blood vessel models into brain-device applications such as flow diverters for aneurysms. The University of Leeds spinout, which simulates medical device performance across virtual patient groups, plans to grow its team from 14 to 34.

Avacta Reports 11.4-Month Median PFS for Faridoxorubicin in Salivary Gland Cancer at ESMO 2026

Avacta Therapeutics has reported a median progression-free survival of 11.4 months for faridoxorubicin (AVA6000) in 32 salivary gland cancer patients treated at 310 mg/m² and above in its Phase 1a/1b trial, against historical benchmarks of 6 to 6.7 months from earlier studies. The data, presented at ESMO 2026, included three partial responses, with first efficacy data for next-generation candidate AVA6103 expected in H1 2027.

BioOrbit Completes Six-Week ISS Mission Growing Protein Crystals for Cancer Drugs

BioOrbit has completed a six-week experiment aboard the International Space Station using its Baby BOX-E unit, which the company says achieved the largest-scale production of protein crystals in space to date. The crystals are intended for highly concentrated cancer drugs that could be self-injected at home rather than given as hospital infusions, and the mission follows BioOrbit's £9.8 million seed round in April.

Avacta Presents AVA6103 Preclinical Data in Enhertu-Resistant Tumour Models at ESMO

Avacta Therapeutics has presented preclinical data at ESMO 2026 showing its FAP-targeted drug conjugate AVA6103 produced partial responses in mouse tumour models and stable disease in gastric tumours that had progressed on Enhertu. The Phase 1a FOCUS-01 trial has completed enrolment at its fourth dose level, with first efficacy data expected in H1 2027.